Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia

• Published in: Leukemia research Vol. 38; no. 5; pp. 638 - 647
• Main Authors: Baurska, Hanna, Kiełbiński, Marek, Biecek, Przemysław, Haus, Olga, Jaźwiec, Bożena, Kutner, Andrzej, Marcinkowska, Ewa
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2014
• Subjects: 1 ;25-dihydroxyvitamin D3; Acute myeloid leukemia; Adult; Aged; Aged, 80 and over; Blasts; Cell Differentiation - drug effects; Differentiation; Female; Flow cytometry; fms-Like Tyrosine Kinase 3 - genetics; Hematology, Oncology and Palliative Medicine; Humans; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Male; Middle Aged; Monocytes - cytology; Mutation; Personalized anticancer therapy; Statistical analysis; Vitamin D - analogs & derivatives; Vitamin D analogs; Flow cytometry; Personalized anticancer therapy; Statistical analysis; Blasts; Vitamin D analogs; Differentiation; Acute myeloid leukemia; 1 ;25-dihydroxyvitamin D 3; 1 ;25-dihydroxyvitamin D3; 1 ;25-dihydroxyvitamin D
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2014.03.009

Abstract The differentiation-inducing potential of side-chain modified analogs of vitamins D, compared to the reference compound, 1,25-dihydroxyvitamin D3 , was studied in blast cells from patients with acute myeloid leukemia and in cell lines. Analogs PRI-1906 and PRI-1907 showed increased cell-differentiation activities, PRI-1907 even at a very low concentration. Our study revealed a high variability of individual patients’ blasts in their susceptibility to vitamin D analogs. The blasts of the patients with normal karyotype and with mutated NPM1 reacted to analogs with stronger differentiation than the blasts of the remaining patients, while the blasts with mutated FLT3 receptor reacted with weaker differentiation than the remaining blasts.